This regulatory shift introduces a structured framework for development and characterization of topical drug products and emphasizes the importance of in vitro methods and pharmacokinetics to demonstrate therapeutic equivalence instead of complicated and expensive in-vivo clinical studies. Here, In-vitro Release Testing (IVRT), In-vitro Permeation Testing (IVPT) come into play as principal instruments for proofing equivalence.
This evolution provides pharmaceutical developers with a scientifically robust, cost-efficient, and accelerated alternative to traditional clinical endpoint studies. It applies to locally applied and locally acting medicinal products for cutaneous use, and may be also relevant for other medicines e.g., preparations for auricular or ocular use, and locally acting vaginal products or nails.
For companies ready to adapt, this transition presents a competitive advantage rather than an obstacle. Those who integrate IVRT and IVPT early in their development pipelines will gain:
- Accelerated regulatory timelines through clearly defined equivalence frameworks,
- Reduced clinical study requirements without compromising scientific integrity,
- Enhanced predictability in regulatory outcomes across the EU market.
With over 25 years of expertise in topical drug formulation development, Conscio Group operates GxP-compliant facilities capable of handling even Highly Active Pharmaceutical Ingredients (HAPIs) and controlled substances (narcotics). Our integrated technical and regulatory experience ensure scientific reliability across a variety of formulation classes, and tissue types from artificial membranes to ex vivo tissue for IVRT and IVPT studies.
This white paper distils the new EMA guideline into actionable insights, outlining the stepwise equivalence framework, detailing the technical requirements for IVRT and IVPT, and highlighting strategic pathways for faster and more predictable product development.
EMA’s New Equivalence Pathway
The EMA guideline introduces a structured, three-tier framework for demonstrating therapeutic equivalence of locally applied, locally acting medicinal products.
Therapeutic equivalence implies that the test and reference products are similar in efficacy and safety that no clinically relevant difference can be expected. The guideline applies to a wide spectrum of cutaneous dosage forms, including dermal, vaginal, ocular, auricular, and nail formulations, such as patches, liquids, and semi-solids like creams, gels, and ointments.
Stepwise Approach to Equivalence
The EMA guideline adopts a stepwise approach that prioritizes in vitro evidence over clinical studies wherever scientifically justified. The principle is to demonstrate equivalence through a sequence of progressively complex methods, moving from physicochemical comparability to in vitro performance testing, and only, when necessary, to pharmacodynamic or clinical endpoint studies.
The choice of testing level depends primarily on the formulation complexity:
- Simple formulations are single-phase systems in which the active ingredient (API) is in solution or suspension within a matrix or vehicle without penetration-enhancing excipients.
- Complex formulations are multi-phase systems, which are difficult to structurally characterize (e.g. emulsions), formulations with excipients that are difficult to characterise or products containing penetration enhancers.
Decision Tree explained
Translated into Action
- Tree 1: Pharmaceutical Equivalence and IVRT Sufficiency
- Tree 2: Permeation Kinetic Studies Required/ IVRT and IVPT necessary
- Tree 3: Clinical or Pharmacodynamic Studies Required
This stepwise framework allows sponsors to match the level of evidence to the complexity of the formulation, ensuring both scientific proportionality and regulatory consistency.
For simple formulations, equivalence can often be demonstrated through IVRT alone, provided that Q1, Q2, and Q3 degree of formulation similarity are established (Tree 1). Meaning if a topical pharmaceutical product has same qualitative composition (Q1) and similar quantitative composition (Q2), equivalence can be concluded if similar physicochemical properties (Q3) are shown.
In complex formulations, IVPT studies become necessary to assess permeation kinetics and ensure bioequivalence (Tree 2).
For both simple and complex formulations, tree 3 meaning pharmacodynamic or clinical endpoint studies are required, if pharmaceutical equivalence and equivalent permeation kinetics cannot be demonstrated.
Technical Framework for IVRT and IVPT Studies
When indicated by the regulatory decision framework, IVRT and/or IVPT serve as key evidence to establish quality and therapeutic equivalence for many topical products. (Tree 1: IVRT; Tree 2: IVRT + IVPT). However, any performed IVRT/IVPT studies must follow appropriate GxP principles to ensure data integrity and regulatory acceptability.
In Vitro Release Testing (IVRT) Requirements
Technical Specifications
- System: Franz diffusion cells (~12 mL receptor volume, ~2 cm² diffusion area)
- Temperature: Maintain membrane surface at 32 °C ± 1 °C.
- Membrane: Synthetic (e.g., cellulose nitrate, polycarbonate, polyester), inert, non-rate-limiting, compatible with formulation, prevents back diffusion.
- Receptor Medium: Demonstrate API stability and sink conditions (≥3–10× saturation volume); pH constant throughout test.
- Dose Application: Pseudo-infinite dose, uniform spreading (±10%), minimal evaporation.
- Duration: Sufficient to capture linear range of release profile w/o >30% dose depletion.
- Sampling: At least n = 6, in linear region.
- Mixing: Controlled stirring to maintain homogeneity.
Validation Parameters
- Linearity: Cumulative amount vs. √time must be linear (r² ≥ 0.90).
- Precision: CV ≤10% intra-run, inter-run, intermediate precision.
- Discriminatory Power: Detect differences in strength and formulation changes (CQAs).
- Robustness: Assess mixing rate, receptor medium, temperature, and application method.
- Analytical Method: Validate per ICH M10.
- Sample Size: ≥12 cells per batch for validation; ≥6 for routine QC.
In Vitro Permeation Testing (IVPT) Requirements
Technical Specifications
- System: Franz diffusion cells (~12 mL receptor volume, ~2 cm² diffusion area).
- Skin Source: Adult human skin, documented donor info (age, sex, anatomical site).
- Integrity Testing: Validate barrier integrity using e.g. TEER.
- Replicates: ≥12 donors, ≥2 replicates per donor.
- Dose Application: Based on SmPC posology; homogeneous spreading.
- Receptor Phase: Buffered aqueous solution (pH ~7.4); demonstrate API stability and sink conditions (≥3–10× saturation volume).
- Temperature: Maintain skin surface at 32 °C ± 1 °C.
- Duration: Typically, 24 h.
- Sampling: Frequent intervals to capture Jmax and decline phase; ≥6–8 time points.
- Controls: A formulation statistically different and non-equivalent to reference.
- Mass Balance: Recovery of 90–110% across compartments.
Validation Parameters
- Discriminatory Power: Detect differences in formulation CQAs (e.g., excipient composition, rheology); use meaningful changes, not omission of excipients.
- Precision: CV ≤15% for Jmax and Atotal.
- Robustness: Assess variations in receptor medium, temperature, mixing, and application.
- Analytical Method: Validate per ICH M10
Implementation Challenges
While the EMA guideline provides a clear framework for IVRT and IVPT studies, its practical implementation often presents technical, regulatory, and operational challenges. Understanding these risks early and addressing them systematically is essential to ensure regulatory acceptance and avoid costly redevelopment cycles.
- Method Development Complexity:
IVRT and IVPT requires specialized expertise and sophisticated equipment. - Validation Requirements:
Comprehensive validation per ICH guidelines demands significant resource - Statistical Compliance:
Meeting stringent acceptance criteria requires robust study design and - Documentation and regulatory:
Clear justifications and scientific reasoning are essential.
Strategic Implications of the EMA Guideline
The IVRT/IVPT market is experiencing unprecedented growth, driven by regulatory recognition of in vitro methodologies as reliable tools for demonstrating therapeutic equivalence. The new EMA guideline reinforces this trend, establishing a harmonized and science-based pathway for topical product development across Europe.
- Accelerated development timelines – IVRT and IVPT reduce reliance on clinical endpoint studies, shortening time-to-market, enabling early formulation optimization.
- Regulatory clarity – Defined equivalence criteria (Q1–Q3) and statistical acceptance ranges bring consistency across EU submissions.
- Cost and resource efficiency – Laboratory-based methods minimize clinical expenditures and allow parallel development programs.
- Strategic advantage – Early alignment with the guideline strengthens regulatory credibility and competitive positioning.
The transition from regulatory understanding to practical execution requires a structured roadmap. The following timeline outlines how organizations can align their development strategies, technical capabilities, and regulatory planning with the new EMA requirements.
Immediate Actions (0–6 months)
- Regulatory Gap Analysis – Assess current testing capabilities and documentation against EMA expectations.
- Method Development Planning – Define target products and initiate protocol design for discriminatory IVRT and IVPT methods.
- Regulatory Strategy Alignment – Establish a coordinated approach between R&D, QA, and regulatory affairs for ongoing projects.
Medium-Term Actions (6–18 months)
- Standardization – Develop and validate IVRT/IVPT methods under GxP-compliance
- Integration into Quality Systems – Implement standardized testing procedures and documentation templates across departments.
- Training and Knowledge Building – Strengthen internal expertise through cross-functional workshops and regulatory updates.
Long-Term Positioning (18+ months)
- Innovation Pipeline Integration – Embed IVRT and IVPT into early formulation development for new and lifecycle products.
- Technology Investment – Expand capacity through advanced diffusion systems and automated data analysis platforms.
- Strategic Partnerships – Build collaborations with specialized laboratories and CROs to sustain long-term technical excellence.
By combining early assessment, structured validation, and long-term capability building, companies can fully leverage the advantages of the new EMA framework — transforming compliance into competitive strength.
EMA Guideline in Practice: The Conscio Approach
Conscio Group translates the new EMA guideline into practical, compliant, and scientifically robust solutions. Our integrated framework connects formulation science, in vitro testing, and regulatory strategy to ensure that every study meets both technical and EMA expectations.
Technical capablities
- State-of-the-art IVRT and IVPT laboratories, equipped for testing across diverse topical dosage forms.
- GxP-compliant method development and validation, ensuring data integrity and reproducibility.
- Human skin procurement and integrity testing protocols for reliable IVPT outcomes.
- Statistical evaluation and regulatory reporting, aligned with ICH and EMA requirements.
Regulatory Expertise
- Comprehensive interpretation of the EMA guideline and tailored implementation.
- Support throughout the marketing authorization process
- Variation and lifecycle management consulting, enabling compliant updates and product optimization.
- Cross-border regulatory harmonization, facilitating submissions across the EU.
Strategic integration
- Embedding regulatory affairs within development programs, ensuring that equivalence considerations guide formulation decisions from the start.
- Quality by Design (QbD) principles applied to topical product development.
- Post-approval change management supported by validated, reproducible in vitro
